Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases (NCT06585670) | Clinical Trial Compass
CompletedNot Applicable
Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases
United States100 participantsStarted 2024-08-26
Plain-language summary
The proposed study is a block-randomized, controlled trial to evaluate the effects of a digital meditation and mindfulness practice on mental health in patients with non-infectious uveitis.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Is 18 or older at time of enrollment.
* Is willing to download Calm Health on their smartphone
* Is able to operate a smartphone \& Calm Health without assistance
* Is able to read words on a screen without assistance
* Diagnosis of non-infectious uveitis
Exclusion Criteria:
* Is under 18 at time of enrollment.
* Has started taking a new anti-depressant, anti-anxiety, or other psychiatric medication to improve mood within the past month.
* Plans to start taking a new anti-depressant, anti-anxiety, or other psychiatric medication to improve mood in the next 12 weeks.
* Has started any type of psychotherapy within the past 3 months.
* Plans to start any type of psychotherapy within the next 12 weeks.
* Already has a mindfulness/meditation app on their smartphone.
* Is unable to operate a smartphone or read words on a screen without assistance.
* Is unable or unwilling to download the Calm Health app on their smartphone.
* Does not consent to their anonymized data being collected via Calm Health app.
What they're measuring
1
Anxiety Symptoms
Timeframe: The primary outcome will be measured at 8 weeks.